A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Zepbound’s results were relatively unchanged year over year, though the number of U.S. patients starting on the medication in 2023 was limited since it did not launch until November of that year.

Zepbound brought in $2.3 billion in U.S. sales during this year's first quarter, making it one of drugmaker Eli Lilly's best sellers. Novo Nordisk says Wegovy has about 200,000 weekly ...

Zepbound is a medication containing tirzepatide, which the preliminary study showed to be more effective for weight loss than Wegovy, which contains semaglutide.

Sixty-three percent of patients starting on Novo Nordisk's Wegovy or Eli Lilly's Zepbound during the first quarter of 2024 were still taking them 12 months later. News. Today's news; US; ...